A new study by UC Davis researchers provides evidence that methods using human bone marrow-derived stem cells to deliver gene therapy to cure diseases of the blood, bone marrow and certain types of cancer do not cause the development of tumors or leukemia. The study was published online in the May 6, 2008 issue of Molecular Therapy.

"The results of our decade-long study of adult human stem cell transplantation shows that there is little risk of adverse events caused by gene transfer, and that adult human stem cells do not pose a cancer risk when implanted into different organs," said Jan Nolta, senior author of the study and director of the UC Davis Stem Cell Program.

Nolta and her colleagues tested the safety of gene transfer into bone marrow stem cells from human donors in more than 600 mice. None of the transplanted mice developed leukemia or solid tumors caused by the gene therapy treatment, during the evaluation period of up to 18 months.

NEWPORT NEWS, Virginia, May 6 /PRNewswire/ --

- Gamma Camera sales to be launched in Europe

Dilon Technologies announced today that it has received CE Mark (Conformite Europeenne) approval for the commercial sale of the Dilon 6800 Gamma Camera in European Union member countries. The Dilon system is a high-resolution gamma camera that enables molecular imaging of the breast and other small organs for early cancer detection.

TORONTO, May 6 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.

CORAL GABLES, Florida, May 6 /PRNewswire/ --

- Acquisition of dermal filler product enhances company's aesthetic portfolio

Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, announced today that it has acquired ABR Invent and ABR Development, developers of the dermal filler Atlean(R).

Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both ABR Invent and ABR Development are legal entities based in France.

MONTREAL, May 6 /PRNewswire/ --

MOUNTAIN VIEW, California and STOCKHOLM, Sweden, May 6 /PRNewswire/ --

- Investment highlights growth in worldwide railway control, command and signaling technology

Synopsys, Inc. (Nasdaq: SNPS), a world leader in software and IP for semiconductor design and manufacturing, and Prover Technology AB today announced that Synopsys has invested in Prover, which supplies signaling design automation solutions for engineering the safety critical systems that control trains, switches and signals. The funds will enable Prover to accelerate its research and development efforts and expand its operations in Europe, North America and Asia.

HAIFA, Israel, May 6 /PRNewswire/ -- Oil Refineries Ltd. (TASE: ORL.TA) (the "Company"), Israel's largest oil refiner, announced today the convening of an Extraordinary General Meeting. See below announcement translated from Hebrew.

Notice is hereby given that, on June 10, 2008, at 10:00 a.m., an Extraordinary General Meeting of the Company's Shareholders shall convene, at the Company's offices, located on the 26th floor of the Azrieli Centre, Square Building, 132 Menachem Begin Street, Tel Aviv, Israel, for the purpose of approving the following resolutions:

On the agenda:

Purchasing a Directors' and Position Holders Liability Insurance

GAITHERSBURG, Maryland, May 6 /PRNewswire/ --

WASHINGTON, DC, May 6 /PRNewswire/ --

- International Reach of 'Young Minds in Psychiatry' Awards is Boosted With AstraZeneca Support